These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 26902765)

  • 21. Pharmacokinetics of meropenem in critically ill patients receiving continuous venovenous haemofiltration: a randomised controlled trial of continuous infusion versus intermittent bolus administration.
    Jamal JA; Mat-Nor MB; Mohamad-Nor FS; Udy AA; Wallis SC; Lipman J; Roberts JA
    Int J Antimicrob Agents; 2015 Jan; 45(1):41-5. PubMed ID: 25455853
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of the pharmacodynamics of meropenem in healthy volunteers following administration by intermittent infusion or bolus injection.
    Jaruratanasirikul S; Sriwiriyajan S
    J Antimicrob Chemother; 2003 Sep; 52(3):518-21. PubMed ID: 12917242
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Meropenem-RPX7009 Concentrations in Plasma, Epithelial Lining Fluid, and Alveolar Macrophages of Healthy Adult Subjects.
    Wenzler E; Gotfried MH; Loutit JS; Durso S; Griffith DC; Dudley MN; Rodvold KA
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7232-9. PubMed ID: 26349830
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bioequivalence, antibacterial activity and therapeutic outcome of a generic meropenem (Mapenem).
    Leelarasamee A; Rongrungruang Y; Trakulsomboon S; Pongpech P; Thanawattanawanich P; Jithavech P
    J Med Assoc Thai; 2008 Jul; 91(7):980-8. PubMed ID: 18839835
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacodynamics of meropenem in critically ill patients with ventilator-associated pneumonia.
    Jaruratanasirikul S; Kositpantawong N; Jullangkoon M; Aeinlang N; Wongpoowarak W
    J Med Assoc Thai; 2013 Oct; 96(10):1283-9. PubMed ID: 24350408
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics and pharmacodynamics of meropenem in children with severe infection.
    Kongthavonsakul K; Lucksiri A; Eakanunkul S; Roongjang S; Issaranggoon Na Ayuthaya S; Oberdorfer P
    Int J Antimicrob Agents; 2016 Aug; 48(2):151-7. PubMed ID: 27345269
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics of meropenem determined by microdialysis in the peritoneal fluid of patients with severe peritonitis associated with septic shock.
    Karjagin J; Lefeuvre S; Oselin K; Kipper K; Marchand S; Tikkerberi A; Starkopf J; Couet W; Sawchuk RJ
    Clin Pharmacol Ther; 2008 Mar; 83(3):452-9. PubMed ID: 17687272
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Might real-time pharmacokinetic/pharmacodynamic optimisation of high-dose continuous-infusion meropenem improve clinical cure in infections caused by KPC-producing Klebsiella pneumoniae?
    Pea F; Della Siega P; Cojutti P; Sartor A; Crapis M; Scarparo C; Bassetti M
    Int J Antimicrob Agents; 2017 Feb; 49(2):255-258. PubMed ID: 28012683
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of the pharmacodynamic profile of commonly used intravenous vancomycin dosing schemes in patients on automated peritoneal dialysis.
    Cardone KE; Chen WZ; Grabe DW; Batzold A; Manley HJ; Lodise TP
    J Antimicrob Chemother; 2014 Jul; 69(7):1873-6. PubMed ID: 24722842
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of intermittent intravenous cefazolin and tobramycin in patients treated with automated peritoneal dialysis.
    Manley HJ; Bailie GR; Frye R; Hess LD; McGoldrick MD
    J Am Soc Nephrol; 2000 Jul; 11(7):1310-1316. PubMed ID: 10864588
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetic profiles of ceftazidime after intravenous administration in patients undergoing automated peritoneal dialysis.
    Kim K; Hwang YH; Ro H; Oh YK; Kim MG; Yu KS; Shin KH; Jang IJ; Shin SG; Ahn C; Oh KH
    Antimicrob Agents Chemother; 2011 Jun; 55(6):2523-7. PubMed ID: 21402833
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Are interstitial fluid concentrations of meropenem equivalent to plasma concentrations in critically ill patients receiving continuous renal replacement therapy?
    Varghese JM; Jarrett P; Wallis SC; Boots RJ; Kirkpatrick CM; Lipman J; Roberts JA
    J Antimicrob Chemother; 2015 Feb; 70(2):528-33. PubMed ID: 25336163
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of 30-min and 3-h infusion regimens for imipenem/cilastatin and for meropenem evaluated by Monte Carlo simulation.
    Lee LS; Kinzig-Schippers M; Nafziger AN; Ma L; Sörgel F; Jones RN; Drusano GL; Bertino JS
    Diagn Microbiol Infect Dis; 2010 Nov; 68(3):251-8. PubMed ID: 20851549
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dosing regimen of meropenem for adults with severe burns: a population pharmacokinetic study with Monte Carlo simulations.
    Ramon-Lopez A; Allen JM; Thomson AH; Dheansa BS; James SE; Hanlon GW; Stewart B; Davies JG
    J Antimicrob Chemother; 2015 Mar; 70(3):882-90. PubMed ID: 25362574
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Meropenem removal in critically ill patients undergoing sustained low-efficiency dialysis (SLED).
    Deshpande P; Chen J; Gofran A; Murea M; Golestaneh L
    Nephrol Dial Transplant; 2010 Aug; 25(8):2632-6. PubMed ID: 20181801
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Application of HPLC to meropenem determination in plasma samples of patients with infections treated after coronary artery bypass graft surgery].
    Bafeltowska J; Pokorska A; Białek K; Wilczyński M
    Rocz Panstw Zakl Hig; 2010; 61(3):323-7. PubMed ID: 21365870
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of high-dose extended-infusion meropenem during pulmonary exacerbation in adult cystic fibrosis patients: a case series.
    Delfino E; Fucile C; Del Bono V; Marchese A; Marini V; Coppo E; Casciaro R; Minicucci L; Giacobbe DR; Martelli A; Viscoli C; Mattioli F
    New Microbiol; 2018 Jan; 41(1):47-51. PubMed ID: 29313863
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antibacterial activity of achievable epithelial lining fluid exposures of Amikacin Inhale with or without meropenem.
    So W; Crandon JL; Hamada Y; Nicolau DP
    J Antimicrob Chemother; 2016 Feb; 71(2):428-37. PubMed ID: 26559690
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Population pharmacokinetics of meropenem during continuous infusion in surgical ICU patients.
    Kees MG; Minichmayr IK; Moritz S; Beck S; Wicha SG; Kees F; Kloft C; Steinke T
    J Clin Pharmacol; 2016 Mar; 56(3):307-15. PubMed ID: 26222202
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Extended versus bolus infusion of meropenem and piperacillin: a pharmacokinetic analysis.
    De Waele J; Carlier M; Hoste E; Depuydt P; Decruyenaere J; Wallis SC; Lipman J; Roberts JA
    Minerva Anestesiol; 2014 Dec; 80(12):1302-9. PubMed ID: 24762706
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.